We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Prototype DNA Enzyme Drug Stops Cancer Growth

By Biotechdaily staff writers
Posted on 25 Jul 2006
While enzymes are usually proteins, a team of researchers has used a novel DNA enzyme (DNAzyme) to inhibit the c-Jun transcription factor, a principal regulator of inflammation and cancer cell growth.

A DNAzyme is a DNA molecule with a catalytic action. More...
These substances are also referred to as deoxyribozymes, DNA enzymes, and catalytic DNA. DNAzymes are associated with gene replication only, and they exist only in the laboratory, but there they are very powerful research tools. DNAzymes were first used in lead-ion dependent RNA cleaving. In the 10 or so years since, many other DNAzymes have been created, each with a specific action. DNA ligases are particularly interesting because they are exceptionally chemoselective when applied to RNA branching reactions, with each ligase adhering to only one specific branch. DNAzymes are also used as metal biosensors, detecting heavy metals completely organically.


Investigators at the University of New South Wales (Sydney, AU; www.unsw.ed.au) used the DNAzyme Dz13 to inhibit c-Jun expression in squamous cell carcinoma (SCC) cells. They found that Dz13 inhibited SCC proliferation and suppressed solid SCC tumor growth and tumor angiogenesis in severe combined immunodeficient mice. Dz13 also suppressed the expression of vascular endothelial growth factor and fibroblast growth factor-2 in the tumors. These findings were reported in the June 19, 2006, online edition of Oncogene.


In a second paper published in the July 2006 issue of Nature Biotechnology, inhibition of c-Jun by Dz13 was shown to reduce joint swelling, inflammatory cell infiltration, and bone erosion in a mouse model of rheumatoid arthritis.

"C-Jun is an important disease-causing gene,” said senior author Dr. Levon Khachigian, professor of molecular biology at the University of New South Wales. "It stands out because we do not see much of it in normal tissue, but it is highly expressed in diseased blood vessels, eyes, lungs, joints, and in the gut--in any number of areas involving inflammation and aggressive vascular growth. Our experimental drug, Dz13, is like a secret agent that finds its target, c-Jun, within the cell and destroys it. Conventional anti-inflammatory drugs are associated with a whole host of side effects. Our therapeutic may potentially avert some of these.”




Related Links:
University of New South Wales

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.